1. Lilly Grant Funding Disclosure May 27, 2008

2. Reactions to Publications Grant Funding Publishing Methodology
Eli Lilly Philosophy
Reactions to Publications
Grant Funding Publishing Methodology
How to Publish
Pre and Post Publication Thoughts 2

3. What to publish in the future? Public Scrutiny and Press
Best Interests
of Industry
Why publish?
What to publish (CME, Charitable, Sponsorship, Clinical Trials, Patient Advocacy)?
What to publish in the future?
Public Scrutiny
and Press
Senate Finance
Committee Inquiries
Why publish?:
Create transparency to public
Highlight the good programs that Lilly and Pharma support
At the time we had two Senate Finance Committee inquiries regarding grant funding and the subject of grant giving by pharma being used for off-label drug promotion was often in the press.
Also states were expanding creating broad legislation regarding spending and gifts from Pharma companies to physicians, some of which included the benefit received by physicians for CME programs.
Discuss that Lilly was the first to launch a clinical trial registry back in 2005(?) to create greater transparency of their clinical studies and to the quality of those studies.
Aggregate
Spend and
State Law
Reporting

4. Physician Participants Non-Physician Participants
Promote Good Work of Pharma
Physician Education
Other Healthcare Practitioner Education
Charitable Contributions
ACCME Programs
Hours of Instruction
Physician Participants
Non-Physician Participants
Grand Total
93,582
712,163
8,255,017
4,577,078
Hit bullets and then cite ACCME 2006 Annual report statistics regarding number of programs and HCP’s educated
Source: ACCME 2006 Annual Report 4 4

5. Government
Press
Industry
Advocacy
Groups
Internal
Praise from Senator Grassley and Capitol Hill for initiative
Consulted on other initiatives (gained added credibility)
N/A
Clarification what is disclosed
Enough disclosure
Other data to be disclosed
Other Pharma company plans
Lilly has no additional plans
Positive articles in WSJ, trade press, et. al.
N/A
Why did Lilly decide to disclose
What is the purpose
Create Transparency
Highlight the good programs Lilly supports
Generally positive
Companies looking to undertake similar initiatives
Moved transparency dialogue to forefront
N/A
Did Lilly do too much too fast
Did Lilly drive the Sunshine Act and other regulations
Right information to publish
Thought this was the right information to disclose
Pros
Positive recognition
Improve awareness of good programs
Improved credibility
Additional scrutiny
Exposure for smaller groups strains resources
N/A
Senior management supportive
Employees feel good about what company is doing
N/A
Want more information about programs
Ongoing assessment of areas for disclosure and transparency
Cons
Questions
Response 5

6. Potential Publishing Methodology
Technical
Challenges
Data Repository
Approving data for publication
Consistency, accuracy of data
Controls
Separation of divisions (Sales, Marketing, etc.)
Following processes and procedures
Documentation
SOPs
LOA language
Responses
Disclosure
Level of detail
Responsible party
Validity of data
Format of disclosure
Preparation & Training
Whom to train
Why train
Continuous training
Potential Publishing Methodology
Discuss new training created and required for all US ee’s narrated by Dr. Alan Breier, VP Medical and Chief Medical Officer
Need to ensure all US ee’s understand external regulations regarding grants since grants will be publicly disclosed and understand appropriate interactions with HCP’s and HC organizations regarding grants
One US policy on grants and consistent SOP’s in the various areas within the company that give grants
Disclosure report process and reviews that occur prior to posting (LGO, legal, Compliance, and Advocacy folks) to ensure information is accurate and has a clear grant description
Discuss technical challenges- one grant application for all areas, one process, consistent SOP’s, coordination and communication across grant offices, etc

7. Publication Experience
Positive reactions internally and externally. No challenges from funding recipients
Contacting key organizations before publication was beneficial and helped industry perception
No noticeable change in provider interaction with Lilly
Preparation and training is key to successfully publishing grant information
Discussion Items
Is disclosing more or less grant detail information better?
What has been the government’s reaction?
Has the perception of the industry changed?
Missing qualitative aspect of our funding.
How good was it? How effective was it?
Use surveys or other criteria to determine this. 7 7